Sanofi SA Q4 2023 Earnings Call Transcript - Thomson StreetEvents

Sanofi SA Q4 2023 Earnings Call Transcript

Sanofi SA Q4 2023 Earnings Call Transcript - Thomson StreetEvents
Sanofi SA Q4 2023 Earnings Call Transcript
Published Feb 01, 2024
19 pages (12275 words) — Published Feb 01, 2024
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of SASY.PA earnings conference call or presentation 1-Feb-24 1:30pm GMT

  
Brief Excerpt:

...Thank you for joining in Sanofi's fourth quarter and full year 2023 results, followed by a Q&A session. As usual, you can find the slides to this call on the Investors page of our website at sanofi.com. Moving to Slide 3. I would like to remind you that information presented in this call contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. I refer you to our Form 20-F document on file with the SEC and also our (foreign language) for a description of these risk factors. With that, please advance to Slide 4. Our speakers on the call today are Paul Hudson, Chief Executive Officer; Houman Ashrafian, Global Head of R&D; Jean-Baptiste de Chatillon, Chief Financial Officer; and the Global Business Unit Heads, Brian Foard, Thomas Triomphe, Olivier Charmeil and Julie Van Ongevalle. (Operator Instructions). And with that, I'd like to turn the call over to Paul. Paul Hudson ...

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
Sanofi SA
Ticker
SASY.PA
Time
1:30pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Jo Walton - UBS Investment Bank, Research Division - Analyst : Can you hear me?

Question: Jo Walton - UBS Investment Bank, Research Division - Analyst : I'm sorry. I have a question on the consumer side, please. Just looking at any progress on the Rx OTC switch trials that you're doing for Tamiflu and Cialis, just thinking as to whether they will -- how visible they will be at the point of separation going forward. And secondly, just on the timing of your COPD launch. I know that you've filed and you don't yet know the time frame of that review. Do you have a priority review voucher? Could we assume that you would use that for such an important launch?

Table Of Contents

Sanofi SA Q2 2024 Earnings Call Transcript – 2024-07-25 – US$ 54.00 – Edited Transcript of SASY.PA earnings conference call or presentation 25-Jul-24 12:30pm GMT

Sanofi SA at Goldman Sachs Global Healthcare Conference Transcript – 2024-06-11 – US$ 54.00 – Edited Transcript of SASY.PA presentation 11-Jun-24 12:00pm GMT

Sanofi SA Q1 2024 Earnings Call Transcript – 2024-04-25 – US$ 54.00 – Edited Transcript of SASY.PA earnings conference call or presentation 25-Apr-24 12:30pm GMT

Sanofi SA at Leerink Partners Global Biopharma Conference Transcript – 2024-03-12 – US$ 54.00 – Edited Transcript of SASY.PA presentation 12-Mar-24 2:40pm GMT

Sanofi SA at TD Cowen Health Care Conference Transcript – 2024-03-04 – US$ 54.00 – Edited Transcript of SASY.PA presentation 4-Mar-24 5:50pm GMT

Sanofi SA R&D Day Transcript – 2023-12-07 – US$ 54.00 – Edited Transcript of SASY.PA corporate analyst meeting</ 7-Dec-23 1:30pm GMT

Sanofi SA Q3 2023 Earnings Call Transcript – 2023-10-27 – US$ 54.00 – Edited Transcript of SASY.PA earnings conference call or presentation 27-Oct-23 12:30pm GMT

Sanofi SA at Bank of America Merrill Lynch Global Healthcare Conference Transcript – 2023-09-13 – US$ 54.00 – Edited Transcript of SASY.PA presentation 13-Sep-23 9:50am GMT

Sanofi SA at Morgan Stanley Global Healthcare Conference Transcript – 2023-09-12 – US$ 54.00 – Edited Transcript of SASY.PA presentation 12-Sep-23 2:10pm GMT

Sanofi SA at Citi BioPharma Conference Transcript – 2023-09-06 – US$ 54.00 – Edited Transcript of SASY.PA presentation 6-Sep-23 5:50pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Sanofi SA Q4 2023 Earnings Call Transcript" Feb 01, 2024. Alacra Store. May 21, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/Q4-2023-Sanofi-SA-Earnings-Call-T15816994>
  
APA:
Thomson StreetEvents. (2024). Sanofi SA Q4 2023 Earnings Call Transcript Feb 01, 2024. New York, NY: Alacra Store. Retrieved May 21, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Q4-2023-Sanofi-SA-Earnings-Call-T15816994>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.